Table 1.
A summary of the ProScreen pilot study results.
| Trial centre | Total | ||
|---|---|---|---|
| Tampere | Helsinki | ||
| Invited, N | 200 | 199* | 399 |
| Consented, N (%) † | 85 (43) | 85 (43) | 170 (43) |
| Previous PSA, N (%) ‡ | 61 (72) | 51 (61) | 112 (66) |
| Previous prostate biopsy, N ‡ | 2 (2) | 5 (6) | 7 (4) |
| Blood sample obtained, N (%) † | 81 (41) | 77 (39) | 158 (40) |
| PSA ≥3 ng/mL, N (%) ‡ | 13 (16) | 14 (18) | 27 (17) |
| Median PSA in men with PSA ≥3 ng/mL, ng/mL | 4.4 | 5.5 | 5.0 |
| Kallikrein panel ≥7.5%, N (%) ‡ | 9 (69) | 13 (93) | 22 (81) |
| mpMRI negative/PI‐RADS v2 score <3, N (%) ‡ | 6 (67) | 6 (46) | 12 (55) |
| mpMRI suspect | |||
| PI‐RADS v2 score 3, N (%) | 2 (22) | 2 (15) | 4 (18) |
| PI‐RADS v2 score 4/5 | 1 (11) | 5 (38) | 6 (27) |
| Prostate cancer cases detected, N (%) | 2 (67) | 5 (71) | 7 (70) |
| Prostate cancer, Gleason sum 6 | 2 (67) | 0 (0) | 2 (20) |
| Prostate cancer, Gleason sum 7+ | 0 (0) | 5 (100) | 5 (50) |
mpMRI, multiparametric MRI; PI‐RADS, Prostate Imaging Reporting and Data System.
*
1 person was excluded from the invitation list because of sex change.
†
Proportion out of invited men.
‡
Proportion out of men with information available, i.e. those who were included that stage of the screening protocol from PSA to kallikrein panel to MRI to biopsy.